Mymetics Corp (MYMX)

[Work Harder]

Since 2017 Mymetics is developing an improved second malaria vaccine candidate, which includes besides the existing antigens, two other possible antigens which will cover the complete life cycle of the parasite in humans. This vaccine candidate is being developed with funds from the EU and collaborations with the NIH, MVI, the

University of Oxford

and the

Swiss Tropical and Public Health institute.

Pre-clinical data is expected in the second half of 2019.

The transmission blocking malaria vaccine, is in its preclinical stage and Mymetics collaborates with the NIH and LMIV to further advance this promising vaccine. The first initial results from the study showed that the virosome vaccine candidates, at the highest dose tested, generate high antibody titers against the required antigens and they were able to significantly reduce (97-100%) the transmission of the Plasmodium falciparum parasite.

https://www.mymetics.com/vaccine-pipeline/malaria/

Goal of this project is to develop additional peptide mimetics derived from the novel blood stage antigens CyRPA and RH5 and to evaluate their protective efficacy in an innovative P. falciparum infection mouse model.

https://www.swisstph.ch/en/topics/malaria/malaria-vaccines/

Link to Project

https://www.swisstph.ch/en/projects/project-detail/project-action/detail/project-controller/Projects/project/evaluation-of-the-protective-efficacy-of-malaria-blood-stage-vaccine-condidates-in-an-innovative-p/